No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GH Guardant Health
- 28.880
- -0.170-0.59%
Close Jun 28 16:00 ET
- 28.590
- -0.290-1.00%
Post 17:50 ET
3.53BMarket Cap-7367P/E (TTM)
30.000High28.220Low3.79MVolume30.000Open29.050Pre Close109.58MTurnover3.46%Turnover RatioLossP/E (Static)122.37MShares41.06052wk High51.76P/B3.17BFloat Cap15.81052wk Low--Dividend TTM109.77MShs Float181.070Historical High--Div YieldTTM6.13%Amplitude15.810Historical Low28.880Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Top Premarket Gainers
African Agriculture (AAGR) shares surged nearly 72% in recent Friday premarket activity, shaving Thursday's 3% loss. Cosmos Health (COSM) stock was almost 59% higher after the company said Thursday it
Express News | Guardant Health Shares up 3.1% Premarket After Guggenheim Raises to Buy From Neutral
Guggenheim Initiates Guardant Health(GH.US) With Buy Rating, Announces Target Price $36
Guggenheim analyst Subbu Nambi initiates coverage on $Guardant Health(GH.US)$ with a buy rating, and sets the target price at $36.According to TipRanks data, the analyst has a success rate of 42.9% an
Express News | Guardant Health Inc : Guggenheim Raises to Buy From Neutral
American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond
USA News Group News Commentary – According to the American Cancer Society, 2024 will be the first year the USA expects to have more than 2 million...
Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?
Comments
Guardant Health is undervalued, making it a good time to accumulate more holdings. The company's positive future outlook isn't fully reflected in the current share price. Consider financial health before investing.
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)? 1
The recent share price drop may indicate unresolved challenges, despite the company's revenue growth. Investors are advised to ensure they are buying a high-quality business, even when the share price is low.
Guardant Health's high P/S ratio is due to strong revenue performance and promising future growth rates, bolstering shareholder confidence. Given the optimism, a significant stock price drop is unlikely soon.
Substantial insider acquisitions point to optimism for the company's prospects. However, the recent sale by the CIO may suggest some insiders think shares are overvalued. Still, high insider ownership implies alignment of management's interests with shareholders.
Wolfe Research Downgrades $Snowflake(SNOW.US$ to Peer Perform From Outperform
Snowflake (SNOW) has an average rating of outperform and price targets ranging from $105 to $500, according to analysts polled by Capital IQ.
Guggenheim Downgrades $MongoDB(MDB.US$ to Sell From Neutral, Adjusts Price Target to $210 From $205
MongoDB (MDB) has an average rating of outperform and price targets ranging from $180 to $365, according to analysts po...
Snowflake (SNOW) has an average rating of outperform and price targets ranging from $105 to $500, according to analysts polled by Capital IQ.
Guggenheim Downgrades $MongoDB(MDB.US$ to Sell From Neutral, Adjusts Price Target to $210 From $205
MongoDB (MDB) has an average rating of outperform and price targets ranging from $180 to $365, according to analysts po...
18
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg